Incidence and risk factors for graft failure in the modern era of cord blood transplantation

• Published in: Vox sanguinis Vol. 117; no. 12; pp. 1405 - 1410
• Main Authors: Chakrabarty, Jennifer Holter, Glover, Joshua, Schmidt, Sara, Phan, Minh, Bycko, Michelle, Duong, Quyen, Vesely, Sara K., O'Neal, Caroline, Robertson, Chelsie, Davis, Christina, Kratochvil, Kristen, Yuen, Carrie, Khawandanah, Mohamad, Selby, George, Jassim, Rami, Williams, Kirsten M.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.12.2022; S. Karger AG
• Subjects: Antibodies; Antigens; Blood; Cord blood; Cord Blood Stem Cell Transplantation; cord blood transplant; Evaluation; Failure; Female; Females; Fetuses; graft failure; Graft rejection; Graft Survival; Graft vs Host Disease; Grafts; haematopoietic stem cell; Hematopoietic Stem Cell Transplantation; Humans; Mortality; progenitor cell; Rank tests; Retrospective Studies; Risk analysis; Risk Factors; Sex; Survival; Transplantation; Transplants & implants; cord blood transplant; graft failure; progenitor cell; haematopoietic stem cell; transplantation
• ISSN: 0042-9007; 1423-0410
• DOI: 10.1111/vox.13368

Background and Objectives Graft failure (GF) after cord blood transplant (CBT) has decreased with improved supportive care and cord selection strategies. We aimed to evaluate cord blood selection and factors associated with retransplantation on the incidence of GF, determine risk factors for GF including host antibodies to Kell antigen and evaluate survival after GF. Materials and Methods We retrospectively reviewed 84 patients who underwent CBT at the University of Oklahoma between 2000 and 2016 and compared outcomes in patients with/without engraftment by Day 28. The nonengraftment cohort was further divided into patients who underwent retransplantation. Kaplan–Meier curves with log‐rank tests were calculated to assess the association between mortality and engraftment. Results Engraftment following CBT was high at 81%, with 52% engrafting by Day 28 and an additional 29% engrafting by a median of 36 days. Retransplantation led to 88% engraftment at a median of 53 days. Overall, 75% of the 40 patients who did not engraft by Day 28 died. Female sex and total nucleated cell count < 3.5/kg were significantly associated with lack of engraftment and higher mortality. Antibodies to Kell fetal antigen were not identified. Retransplantation by Day 28 for primary GF conferred a survival advantage. Conclusion This study demonstrates that failure to engraft by 28 days was associated with increased mortality, and risk was mitigated with early retransplantation. Female sex and low total cell dose were associated with increased mortality. Early identification of GF coupled with early retransplantation can reduce mortality in CBT.